

CLAIM AMENDMENT

Please amend the claims as follows:

1-27. (Canceled).

28. (Previously Presented) A composition suitable for local, non-systemic administration of a drug to a body and directly to tissue within a body cavity having been subjected to a surgical procedure, said composition consisting of:

a biodegradable polymer in a form selected from the group consisting of film, foam, fibers and filaments;

Tranilast or an analog thereof in an amount effective to inhibit formation of post-operative adhesions upon local, non-systemic administration of said composition to said tissue; and

optionally an additional therapeutic agent in an amount effective to provide the therapeutic effect intended by administration of said therapeutic agent,

wherein said Tranilast analog is selected from the group consisting of N-(2-Acetyl-4,5-dimethoxyphenyl)(4-((phenylamino)carbonylamino)-phenyl)formamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-2-(4-((phenylamino)carbonylamino)phenyl)-ethanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-((phenylamino)carbonylamino)phenyl)prop-2-enamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-((phenylamino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-4-(4-((phenylamino)carbonylamino)phenyl)-butanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(phenylcarbonylamino)carbonylamino)phenyl)-propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(2-phenylacetyl-amino)-phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(phenoxy-carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((2-nitrophenyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((3-nitrophenyl)amino)carbonylamino)-phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((4-nitrophenyl)amino)carbonylamino)phenyl)-

propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((2-aminophenyl)amino)-carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((3-aminophenyl)amino)carbonylamino)phenyl)-propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((4-aminophenyl)amino)carbonylamino)phenyl)-propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((4-fluorophenyl)amino)-carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-di-methoxyphenyl)-3-(4-(((4-acetylphenyl)amino)carbonylamino)phenyl)-propanamide, N-(2-Acetyl-4,5-dimethoxy-phenyl)-3-(4-(((4-methylphenyl)amino)carbonylamino)phenyl)-propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((4-methoxyphenyl)-amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((3,4,5-trimethoxyphenyl)amino)carbonylamino)phenyl)-propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((4-pyridyl)amino)carbonylamino)phenyl)-propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-((benzylamino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxy-phenyl)-3-(4-((butylamino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxy-phenyl)-3-(4-((cyclohexylamino)-carbonylamino)phenyl)propanamide, and a potassium, sodium, calcium and magnesium salt of Tranilast.

29. (Canceled).

30. (Previously Presented) The composition of claim 28 wherein said biodegradable polymer is selected from the group consisting of poloxamers, poly(orthoester)s, poly(vinyl alcohol)s, poly(anhydride)s, poly(methacrylate)s, poly(methacrylamide)s, anionic carbohydrate polymers, poly(hydroxybutyric acid)s, polyacetals, poly(1-lactide), poly(dl-lactide), poly(dl-lactide-co-glycolide)s, poly(1-lactide-co-glycolide)s, poly(e-caprolactone), polyglycolide, poly(p-dioxanone)s, poly(trimethylene carbonate), poly(alkylene diglycolate)s, poly(oxaester)s, poly(oxaamide)s and glyceride polymers.

31. (Original) The composition of claim 28 wherein said composition provides for single dose administration of said Tranilast or analog thereof.

32. (Previously Presented) The composition of claim 28 wherein said composition provides for sustained release of said Tranilast or analog thereof.

33. (Canceled).

34. (Original) The composition of claim 28 comprising from about 0.01 milligram Tranilast or analog thereof per kilogram of the body to about 3,000 milligram Tranilast or analog thereof per kilogram of the body.

35-38. (Canceled).

39. (Currently Amended) The composition of claim 28 wherein said biodegradable polymer is selected from the group consisting of hyaluronic acids, collagens, ~~nonionic triblock copolymers of (polyoxyethylene) and (polyoxypropylene)~~, chitin, chitosans, dextrans, glucoses, carbohydrates, gelatins, glycosaminoglycans, aliginates, starches and polypeptides.

40. (Canceled).

41. (Previously Presented) The composition of claim 28 wherein said additional therapeutic agent is present and is selected from the group consisting of an anti-fibrotic, an anti-inflammatory, an anti-proliferative and an agent that inhibits collagen synthesis.